Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
From Data Disseminator to Trusted Advisor
Summary
In this episode, Chad Fellers shares insights from his experience as an MSL, highlighting his team's success strategies during COVID-19. He discusses the evolving role of MSLs as trusted advisors and offers advice on how to measure and enhance MSL value. Chad explores the future of Key Opinion Leader (KOL) engagement and the influence of digital platforms, as well as adjustments in travel and administrative duties. He emphasizes the importance of active listening and provides tips for MSLs to build strong advisor relationships. The episode also touches on Chad's personal interests, including streaming favorites and dietary changes influenced by documentaries.
Learn about how MSLs go from data disseminators to trusted advisors in my conversation with Chad Fellers, Director of Medical Science Liasons at Harmony Biosciences.
In this episode we discuss:
-
The success of his team despite COVID.
-
The unique approach their team uses in engaging their KOLs.
-
Measuring and assessing value from an MSL perspective.
-
His stance in leading his MSL team.
-
The future of KOL engagement for MSLs.
-
Effect of the change of less travel to MSLs.
-
How it’s going to look like as things open up.
-
Advice for MSLs to stay focused, on track, and continue to be a trusted advisor.
Medical Science Liaisons, MSL team strategies, Key Opinion Leader engagement, MSL value measurement, trusted advisor role
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
Article
Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer
Value assessment of oncology drugs using a weighted criterion-based approach
Article
Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
Article
Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD